Total Payments
$55,762
2019 Payments
$37,032
Companies
6
Transactions
33
Payment Breakdown by Category
Consulting$50,891 (91.3%)
Travel$3,245 (5.8%)
Research$1,386 (2.5%)
Food & Beverage$240.00 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $50,891 | 7 | 91.3% |
| Travel and Lodging | $3,245 | 21 | 5.8% |
| Unspecified | $1,386 | 1 | 2.5% |
| Food and Beverage | $240.00 | 4 | 0.4% |
Payments by Type
General
$54,376
32 transactions
Research
$1,386
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $38,064 | 9 | $0 (2019) |
| BioDelivery Sciences International, Inc. | $11,086 | 8 | $0 (2018) |
| Mallinckrodt LLC | $2,455 | 1 | $0 (2018) |
| Par Pharmaceutical, Inc. | $1,386 | 7 | $0 (2018) |
| Sentynl Therapeutics, Inc. | $1,386 | 7 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $1,386 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $37,032 | 5 | Janssen Research & Development, LLC ($37,032) |
| 2018 | $18,729 | 28 | BioDelivery Sciences International, Inc. ($11,086) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2019 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $20,020.00 | General |
| 11/15/2019 | Janssen Research & Development, LLC | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $765.48 | General |
| Category: Neuroscience | ||||||
| 11/15/2019 | Janssen Research & Development, LLC | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Neuroscience | ||||||
| 03/14/2019 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $16,041.14 | General |
| 03/14/2019 | Janssen Research & Development, LLC | — | Travel and Lodging | Cash or cash equivalent | $80.61 | General |
| 12/06/2018 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $916.62 | General |
| 12/06/2018 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 12/06/2018 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 12/06/2018 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 08/16/2018 | Mallinckrodt LLC | — | Consulting Fee | Cash or cash equivalent | $2,454.80 | General |
| 08/16/2018 | Teva Pharmaceuticals USA, Inc. | Fentora (Drug) | — | Cash or cash equivalent | $1,385.73 | Research |
| Study: Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program • Category: Central Nervous System | ||||||
| 08/16/2018 | Par Pharmaceutical, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,237.50 | General |
| 08/16/2018 | Sentynl Therapeutics, Inc. | Abstral (Drug) | Consulting Fee | Cash or cash equivalent | $1,237.50 | General |
| Category: Pharmacology/Toxicology | ||||||
| 08/16/2018 | Par Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $12.83 | General |
| 08/16/2018 | Par Pharmaceutical, Inc. | — | Travel and Lodging | Cash or cash equivalent | $4.91 | General |
| 06/29/2018 | BioDelivery Sciences International, Inc. | BUNAVAIL 2.1 mg 30-count box (Drug), BUNAVAIL 2.1 mg single pouch, BUNAVAIL 4.2 mg 30-count box | Travel and Lodging | Cash or cash equivalent | $490.20 | General |
| Category: Addiction Therapy | ||||||
| 06/29/2018 | BioDelivery Sciences International, Inc. | BUNAVAIL 2.1 mg 30-count box (Drug), BUNAVAIL 2.1 mg single pouch, BUNAVAIL 4.2 mg 30-count box | Travel and Lodging | Cash or cash equivalent | $303.97 | General |
| Category: Addiction Therapy | ||||||
| 06/29/2018 | BioDelivery Sciences International, Inc. | BUNAVAIL 2.1 mg 30-count box (Drug), BUNAVAIL 2.1 mg single pouch, BUNAVAIL 4.2 mg 30-count box | Travel and Lodging | Cash or cash equivalent | $156.10 | General |
| Category: Addiction Therapy | ||||||
| 06/29/2018 | BioDelivery Sciences International, Inc. | BUNAVAIL 2.1 mg 30-count box (Drug), BUNAVAIL 2.1 mg single pouch, BUNAVAIL 4.2 mg 30-count box | Travel and Lodging | Cash or cash equivalent | $93.60 | General |
| Category: Addiction Therapy | ||||||
| 06/29/2018 | Sentynl Therapeutics, Inc. | Abstral (Drug) | Travel and Lodging | Cash or cash equivalent | $61.28 | General |
| Category: Pharmacology/Toxicology | ||||||
| 06/29/2018 | BioDelivery Sciences International, Inc. | BUNAVAIL 2.1 mg 30-count box (Drug), BUNAVAIL 2.1 mg single pouch, BUNAVAIL 4.2 mg 30-count box | Travel and Lodging | Cash or cash equivalent | $39.30 | General |
| Category: Addiction Therapy | ||||||
| 06/29/2018 | Par Pharmaceutical, Inc. | — | Travel and Lodging | In-kind items and services | $38.00 | General |
| 06/29/2018 | Sentynl Therapeutics, Inc. | Abstral (Drug) | Travel and Lodging | Cash or cash equivalent | $38.00 | General |
| Category: Pharmacology/Toxicology | ||||||
| 06/29/2018 | Par Pharmaceutical, Inc. | — | Travel and Lodging | In-kind items and services | $19.51 | General |
| 06/29/2018 | Sentynl Therapeutics, Inc. | Abstral (Drug) | Travel and Lodging | Cash or cash equivalent | $19.51 | General |
| Category: Pharmacology/Toxicology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program | Teva Pharmaceuticals USA, Inc. | $1,386 | 1 |
About Dr. David Goldsmith, M.D
Dr. David Goldsmith, M.D is a Pediatric Nephrology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2010. The National Provider Identifier (NPI) number assigned to this provider is 1235459967.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Goldsmith, M.D has received a total of $55,762 in payments from pharmaceutical and medical device companies, with $37,032 received in 2019. These payments were reported across 33 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($50,891).
Ad
Practice Information
- Specialty Pediatric Nephrology
- Location New York, NY
- Active Since 06/04/2010
- Last Updated 06/04/2010
- Taxonomy Code 2080P0210X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1235459967
Products in Payments
- BUNAVAIL 2.1 mg 30-count box (Drug) $11,086
- Abstral (Drug) $1,386
- Fentora (Drug) $1,386
- SPRAVATO (Drug) $890.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Nephrology Doctors in New York
Howard Trachtman, Md, MD
Pediatric Nephrology — Payments: $201,480
Pediatric Nephrology $201,480
Hilary Hotchkiss, M.d, M.D
Pediatric Nephrology — Payments: $150,543
Pediatric Nephrology $150,543
Dr. Namrata Jain, Md, MD
Pediatric Nephrology — Payments: $1,126
Pediatric Nephrology $1,126
Dr. Laura Malaga Dieguez, M.d. Ph.d, M.D. PH.D
Pediatric Nephrology — Payments: $578.31
Pediatric Nephrology $578.31
Hilda Fernandez, Md, MD
Pediatric Nephrology — Payments: $387.21
Pediatric Nephrology $387.21
Dr. Marissa Lipton, Md, MD
Pediatric Nephrology — Payments: $311.42
Pediatric Nephrology $311.42